Overview
- Two identical non-inferiority trials, named COMO and CAPRI, will test DURAVYU against on‑label 2 mg aflibercept with redosing every six months and about 240 patients in each study.
- The primary endpoint is change from baseline in best‑corrected visual acuity at weeks 52 and 56, with randomization to study arms occurring on day one.
- EyePoint says first patient dosing is anticipated in the first quarter of 2026 and notes that DURAVYU remains an investigational product not approved by the FDA.
- New preclinical findings indicate vorolanib inhibits IL‑6–mediated inflammation via JAK receptors, particularly JAK‑1, in addition to blocking VEGF‑driven vascular permeability, with data to be presented at the Eyecelerator meeting at AAO 2025.
- The company priced 11,000,000 shares at $12.00 and pre‑funded warrants for up to 1,500,000 shares at $11.999, expecting about $150 million in gross proceeds to fund DURAVYU programs in DME and wet AMD, earlier‑stage pipeline work, and general corporate purposes.